Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Breast Neoplasms 47Neutropenia 26Lymphoma 25Lymphoma, Non-Hodgkin 12Lymphoma, Large B-Cell, Diffuse 12Neoplasms 11Sarcoma 9Lymphoma, Follicular 9Ovarian Neoplasms 8Lymphoma, Mantle-Cell 8Leukemia 8Hodgkin Disease 8Carcinoma, Non-Small-Cell Lung 8Lung Neoplasms 7Leukemia, Lymphocytic, Chronic, B-Cell 7Triple Negative Breast Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Multiple Myeloma 5Lymphoma, B-Cell, Marginal Zone 5Chemotherapy-induced Neutropenia 5Rhabdomyosarcoma 4Neoplasm Metastasis 4Lymphoma, Large-Cell, Immunoblastic 4Burkitt Lymphoma 4Waldenstrom Macroglobulinemia 3Urinary Bladder Neoplasms 3Testicular Neoplasms 3Sarcoma, Synovial 3Prostatic Neoplasms 3Neurofibrosarcoma 3

Interventions

Gemcitabine 2Docetaxel 2pegfilgrastim 1pazopanib 1ixabepilone 1Thalidomide 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Epothilones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Recurrent Uterine Corpus Sarcoma × pegfilgrastim × Clear all
NCT00031629 2016-12-08

Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus

GOG Foundation

Phase 2 Completed
51 enrolled
GynecologicSarcoma

Recurrent Uterine Corpus Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡